Healthcare Industry News: Bristol-Myers Squibb
News Release - February 22, 2017
Mitra Appoints Anton Ehrhardt as Vice President of Medical AffairsBOSTON, Feb. 22, 2017 -- (Healthcare Sales & Marketing Network) -- Mitra Biotech, Inc., a global leader in advancing the personalization of cancer treatment, today announced the appointment of Anton Ehrhardt, Ph.D., as Vice President of Medical Affairs.
"Anton Ehrhardt is a respected leader in Medical Affairs, and brings valuable knowledge and experience to our rapidly growing Mitra team," said Mallik Sundaram, president and CEO of Mitra Biotech. "We're pleased to welcome Anton as we embark upon the U.S. clinical launch of CANscript™ — our phenotypic platform that predicts individual response to treatment — and look forward to his expert guidance as we continue our mission of evolving the landscape of truly personalized cancer treatment and care."
Prior to joining Mitra, Dr. Ehrhardt held Medical Affairs leadership roles at Onyx Pharmaceuticals (Amgen), Sanofi, Millennium Pharmaceuticals, Cubist Pharmaceuticals, and Bristol-Myers Squibb. His responsibilities have included building and overseeing Medical Affairs organizations and investigator-sponsored research programs in the therapeutic areas of oncology and infectious diseases. Dr. Ehrhardt also served as President of the Investigator Initiated Sponsored Research Association (IISRA) during its integration into the Association of Clinical Research Professionals (ACRP).
Dr. Ehrhardt received his Ph.D. from Arizona State University, and B.A. and M.S. degrees from California State University, Northridge.
About Mitra Biotech™
Mitra Biotech is a global leader in advancing personalized oncology treatment and supporting more effective and efficient drug development.
Founded in 2010, Mitra is headquartered in Woburn, MA and maintains a significant research and laboratory presence in Bangalore, India. An accomplished leadership team of industry professionals heads the company, with a dedicated focus on enhancing the personalization of cancer treatment and care worldwide.
Mitra's CANscript is a novel functional platform that replicates an individual patient's unique tumor microenvironment to predict treatment response. CANscript tests physician-selected treatments, measuring a series of response parameters via multiple terminal and kinetic assays. The platform uses a sophisticated, clinical data-trained algorithm to synthesize the evaluated tumor responses into a single score for each treatment tested, reliably predicting treatment response rates and highlighting less effective treatment options. Test results are available in seven days.
CANscript has been validated using thousands of cancer cases, with a published 90% overall correlation1 between the platform's treatment predictions and actual clinical outcomes.
To learn more, please visit www.mitrabiotech.com.
1. Majumder, Biswanath et al, "Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity" Nature Communications, Issue 6, 2015
Source: Mitra Biotech
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.